Skip to main content
TipRanks
Go Ultimate75% OFF

3-D Matrix (DMTRF) AI Stock Analysis

5 Followers
DMTRF

3-D Matrix

(Other OTC:DMTRF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthRevenue has scaled sharply over several years and accelerated again most recently, providing evidence of expanding commercialization for the company’s peptide hemostat. If sustained, this growth can improve operating leverage and strengthen market reach across domestic and international surgical settings.
Negative Factors
Weak Cash ConversionWeak conversion of reported earnings into operating and free cash flow raises questions about earnings quality and the repeatability of recent profits. Persistently modest cash generation could restrict internally funded investment, increase reliance on financing, and limit flexibility during execution setbacks.

3-D Matrix (DMTRF) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%175%DMTRF+61.67%SPY+14.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$310.35M
Dividend Yield
―
Average Volume (3M)
2,051
Price to Earnings (P/E)
10.5
Beta (1Y)
0.11
Revenue Growth
48.40%
EPS Growth
―
Country
US
Employees
129
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

3-D Matrix Business Overview & Revenue Model

Company Description

3-D Matrix, Ltd. specializes in pioneering self-assembling peptide technology. Its flagship product, PuraMatrix, is an innovative self-assembling peptide hydrogel with diverse applications across medical fields, including regenerative medicine, cell...

3-D Matrix Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DMTRF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:6678JP:667882OutperformJPY 18.54B12.09―5.97%17.11%23.02%
JP:6849JP:684965NeutralJPY 260.91B20.30―2.13%-0.18%-33.38%
JP:7963JP:796359NeutralJPY 8.08B9.67―3.04%8.56%7.14%
JP:6523JP:652358NeutralJPY 178.51B17.295.76%2.99%2.74%145.33%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4549JP:454950NeutralJPY 72.79B39.61―2.66%3.92%-52.01%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%DMTRFJP:6523JP:4549JP:6678JP:6849JP:7963Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DMTRF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DMTRF3-D Matrix 2.420.9261.67%
JP:6523PHC Holdings Corp.1404.00468.5150.08%
JP:4549Eiken Chemical Co., Ltd.2182.00-117.10-5.09%
JP:6678Techno Medica Co., Ltd.2162.00281.9014.99%
JP:6849Nihon Kohden Corporation1500.00-74.50-4.73%
JP:7963Koken Ltd.1658.00-138.58-7.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.